https://www.nice.org.uk/guidance/ta814
Overview | Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic...
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis
overviewabrocitinibtralokinumabupadacitinib
https://www.nice.org.uk/guidance/ta856/chapter/3-Committee-discussion
3 Committee discussion | Upadacitinib for treating moderately to severely active ulcerative colitis...
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults
https://www.fiercebiotech.com/keyword/upadacitinib-abt-494
upadacitinib (ABT-494) | Fierce Biotech
abt 494upadacitinibfiercebiotech
https://investingnews.com/chmp-recommends-european-commission-approval-of-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-ulcerative-colitis/
CHMP Recommends European Commission Approval of Upadacitinib for the Treatment of Adults with...
May 24, 2022 - CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance 1-3 Ulcerative colitis is a chronic,...
european commission
https://www.mountsinai.org/clinical-trials/study-to-evaluate-safety-effectiveness-of-upadacitinib-tablets-in-adult-adolescent-participants-with-severe-alopecia-areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent...
https://www.mdpi.com/2227-9059/13/10/2455
A Comparison of the Efficacy and Safety of Ustekinumab and Upadacitinib in Biologically Experienced...
Background/Objectives: Ustekinumab (UST) and upadacitinib (UPA) are molecules that have been used in patients with ulcerative colitis (UC) since 2019 and 2022,...
efficacy and safetyof the
https://www.hmpgloballearningnetwork.com/site/thederm/news/upadacitinib-drives-robust-hair-regrowth-adolescents-and-adults-severe-alopecia
Upadacitinib Drives Robust Hair Regrowth in Adolescents and Adults With Severe Alopecia Areata
Phase 3 subgroup analysis shows significant scalp and facial hair regrowth with upadacitinib, with consistent safety across age groups. Hair and Trichology News
adolescents and adults
https://pmc.ncbi.nlm.nih.gov/articles/PMC11300694/
Budget impact of upadacitinib in patients with moderate to severe rheumatoid arthritis in Argentina...
To analyze the budget impact of upadacitinib (UPA) 15 mg + methotrexate (MTX) for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients...
https://www.hmpgloballearningnetwork.com/site/rheum/advances/rheumatology/jak-inhibitor-shows-superiority-among-certain-patients-ra
Upadacitinib Effective for AS
Clinical trials showed that upadacitinib is effective and safe for patients with axial spondylitis
upadacitinibeffective
https://www.mdpi.com/2077-0383/11/23/6894
The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of...
Background: Our aim was to systematically investigate the effect of upadacitinib, an oral JAK-1 selective inhibitor, on lipid profile and cardiovascular...